Gluco-A Tablet
Acarbose
50mg
Acme Laboratories Ltd.
| Pack size | 20's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 11.04 AED |
Available as:
Indications
Gluco-A Tablet is used for:
Type 2 DM
Adult Dose
Adult:
PO Initial: 25 mg/day q8hr. May adjust gradually.
Maintenance: 50-100 mg 3 times/day.
Maximum Dose
<60 kg: 50 mg 3 times/day.
>60 kg: 100 mg 3 times/day.
Child Dose
Renal Dose
Renal Impairment
CrCl Dosage
<25 Contraindicated.
Administration
Should be taken with food. Take w/ 1st bite of each main meal.
Contra Indications
Patients <18 yr; diabetic ketoacidosis or cirrhosis; malabsorption; inflammatory bowel disease; with or pre-disposed to intestinal obstruction; intestinal diseases that affect digestion or absorption; conditions that worsen as a result of increased gas formation e.g. hernias; colonic ulcers; hepatic impairment; CrClr< 25 ml/min/1.73m2. Pregnancy, lactation.
Precautions
No clinical studies exist establishing conclusive evidence of macrovascular risk reduction with acarbose or any other anti-diabetic drug
When diabetic patients are exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of control of blood glucose may occur; at such times, temporary insulin therapy may be necessary
Hypoglycemia
As per its mechanism of action, drug should not cause hypoglycemia, when administered alone, in the fasted or postprandial state
Sulfonylurea agents or insulin may cause hypoglycemia; because when given in combination with a sulfonylurea or insulin combination treatment will cause further lowering of blood glucose, it may increase the potential for hypoglycemia
Elevated serum transaminase
Treatment-emergent elevations of serum transaminases (AST and/or ALT) above the upper limit of normal (ULN) reported; although differences between treatments were statistically significant, elevations were asymptomatic, reversible, more common in females, and, in general, were not associated with other evidence of liver dysfunction
Monitoring Parameter
Therapeutic response to Acarbose should be monitored by periodic blood glucose tests. Measurement of glycosylated hemoglobin levels is recommended for the monitoring of long-term glycemic control.
Monitor LFT every 3 mth for 1st yr and periodically thereafter especially for doses >50 mg tid. Reduce dose or withdraw therapy if transaminases elevations persist. If hypoglycaemia occurs, give glucose orally as a 1st aid measure.
Adhere strictly to the prescribed diabetic diet to avoid intensification of GI symptoms.
Pregnancy-Lactation
Pregnancy Category: B
Pregnancy
Previously, acarbose was categorized as Category B. Under PLLR, it now has specific labeling.
Data: Limited human studies. Animal studies have not shown evidence of harm, but data are insufficient to confirm safety in pregnancy.
Recommendation: Use only if the potential benefit justifies the potential risk to the fetus.
Lactation
Excretion in Breast Milk: Not well studied. Animal studies show acarbose is excreted in milk.
Recommendation: Use caution if administering to breastfeeding mothers. Consider potential risks and benefits.
Interactions
May enhance effects of other antidiabetics including insulin. Diminished effects w/ GI adsorbents (e.g. charcoal) and digestive enzyme preparations containing carbohydrate splitting enzymes (e.g. amylase, pancreatin). Neomycin and colestyramine may enhance effects of acarbose. May inhibit absorption of digoxin.
Contraindicated (0)
Serious - Use Alternative (2)
ethanol
pramlintide
Adverse Effects
Side effects of Acarbose :
>10%
abdominal pain (19%),diarrhea (31%),elevated serum transaminases, flatulence (74%)
Potentially Fatal: Hepatotoxicity.
Mechanism of Action
Acarbose competitively and reversibly inhibits pancreatic alpha-amylase and intestinal brush border alpha-glucosidases, resulting in retardation of glucose absorption from hydrolysed complex carbohydrates and reduction of blood-glucose concentrations.
Note
Gluco-A 50mg Tablet manufactured by Acme Laboratories Ltd.. Its generic name is Acarbose. Gluco-A is availble in Bangladesh.
Farmaco BD drug index information on Gluco-A Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.